

FORM PTO-1449 (Modified) US DEPARTMENT OF COMMERCE US Patent and Trademark Office				Docket No. 50623.245		Application No. 10/623,908	
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Applicant Paul J. Kawula			
				Filing Date July 21, 2003		Group Art Unit 3731	

RECEIVED

FEB 17 2005

US PATENT & TRADEMARK OFFICE


U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
<i>BP</i>	A1	6,099,561	8/8/00	Alt	623	1.44	
	A2						
	A3						
	A4						
	A5						
	A6						

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
<i>BP</i>	A1	2003/0100865	5/29/03	Santini, Jr. et al.			

FOREIGN PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation Yes No
<i>BP</i>	B1	DE 199 16086	10/14/99	Germany			X
<i>BP</i>	B2	EP 1 236 449	9/4/02	EPO			
<i>BP</i>	B3	WO 02/26281	4/4/02	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages etc.)	
<i>BP</i> C1	International Search Report and Written Opinion for PCT/US2004/022021, filed 7/8/04, mailed 12/28/04, 9 pgs.
EXAMINER <i>Brian Pellegrino</i>	DATE CONSIDERED <i>12/23/05</i>

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.



FORM PTO-1449 (Modified) Approved for use through 10/31/2002 INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.245		Application No. 10/623,908	
Applicant Paul J. Kawula						Filing Date July 21, 2003		Group Art Unit 3731	

U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
<div style="font-size: 2em; margin-top: 10px;">20</div> <div style="font-size: 2em; margin-top: 10px;">1</div> <div style="border-left: 2px solid black; height: 100%; position: relative; margin-left: 10px;"> <div style="position: absolute; top: 0; left: -10px; width: 10px; height: 100%;"></div> </div> <div style="margin-top: 10px;">V</div> <div style="font-size: 2em; margin-top: 10px;">SP</div>	A1	4,329,383	5/11/82	Joh	428	36	7/21/80
	A2	4,459,252	07/10/84	MacGregor	264	46.9	
	A3	4,733,665	3/29/88	Palmaz	128	343	11/7/85
	A4	4,800,882	1/31/89	Gianturco	128	343	3/13/87
	A5	4,882,168	11/21/89	Casey et al.	424	468	9/5/86
	A6	4,886,062	12/12/89	Wiktor	128	343	10/19/87
	A7	4,941,870	7/17/90	Okada et al.	600	36	12/30/88
	A8	4,977,901	12/18/90	Ofstead	128	772	4/6/90
	A9	5,059,211	10/22/91	Stack et al.	606	198	
	A10	5,112,457	5/12/92	Marchant	204	165	7/23/90
	A11	5,163,952	11/17/92	Froix	623	1	
	A12	5,165,919	11/24/92	Sasaki et al.	424	488	9/26/90
	A13	5,272,012	12/21/93	Opolski	428	423.1	1/29/92
	A14	5,292,516	3/8/94	Viegas et al.	424	423	11/8/91
	A15	5,298,260	3/29/94	Viegas et al.	424	486	6/9/92
	A16	5,300,295	4/5/94	Viegas et al.	424	427	9/13/91
	A17	5,306,501	4/26/94	Viegas et al.	424	423	11/8/91
	A18	5,306,286	04/26/94	Stack et al.	606	198	
	A19	5,328,471	7/12/94	Slepian	604	101	8/4/93
	A20	5,330,768	7/19/94	Park et al.	424	501	7/5/91
	A21	5,380,299	1/10/95	Fearnot et al.	604	265	8/30/93
	A22	5,417,981	5/23/95	Endo et al.	424	486	4/28/93
	A23	5,447,724	9/5/95	Helmus et al.	424	426	11/15/93
	A24	5,455,040	10/3/95	Marchant	424	426	11/19/92
	A25	5,462,990	10/31/95	Hubbell et al.	525	54.1	10/5/93
	A26	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93

BP	A27	5,527,337	06/18/96	Stack et al.	606	198	
↑	A28	5,569,463	10/29/96	Helmus et al.	424	426	6/7/95
	A29	5,578,073	11/26/96	Haimovich et al.	623	1	9/16/94
	A30	5,605,696	2/25/97	Eury et al.	424	423	3/30/95
	A31	5,609,629	3/11/97	Fearnott et al.	623	1	6/7/95
	A32	5,624,411	4/29/97	Tuch	604	265	6/7/95
	A33	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
	A34	5,649,977	7/22/97	Campbell	623	1	9/22/94
	A35	5,658,995	8/19/97	Kohn et al.	525	432	11/27/95
	A36	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
	A37	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
	A38	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
	A39	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A40	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
	A41	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
	A42	5,713,949	02/03/98	Jayaraman	623	1	
	A43	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A44	5,735,897	4/7/98	Buirge	623	12	1/2/97
	A45	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A46	5,766,710	06/16/98	Turnlund et al.	428	36.1	
	A47	5,769,883	06/23/98	Buscemi et al.	623	1	
	A48	5,776,184	7/7/98	Tuch	623	1	10/9/96
	A49	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
	A50	5,800,392	9/1/98	Racchini	604	96	5/8/96
	A51	5,820,917	10/13/98	Tuch	427	2.1	6/7/95
	A52	5,824,048	10/20/98	Tuch	623	1	10/9/96
	A53	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
	A54	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
	A55	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
	A56	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
↓	A57	5,843,172	12/01/98	Yan	623	1	
BP	A58	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97

	A59	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
	A60	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A61	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A62	5,873,904	02/23/99	Ragheb	623	1	
	A63	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
	A64	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A65	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
	A66	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A67	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
	A68	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
	A69	5,980,928	11/9/99	Terry	424	427	7/29/97
	A70	5,980,972	11/9/99	Ding	427	2.24	9/22/97
	A71	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
	A72	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A73	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A74	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A75	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
	A76	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A77	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A78	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A79	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A80	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A81	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A82	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A83	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A84	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A85	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A86	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A87	6,120,536	9/19/00	Ding et al.	623	1.43	
	A88	6,120,847	9/19/00	Yang et al.	427	335	
	A89	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A90	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A91	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97

BP	A92	6,129,761	10/10/00	Hubbell	623	11	6/7/95
↑	A93	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A94	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	A95	6,203,551	3/20/01	Wu	606	108	10/4/99
	A96	6,206,915	3/27/01	Fagan et al.	623	1.42	
	A97	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A98	6,240,616	6/5/01	Yan	29	527.2	4/15/97
	A99	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	A100	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
	A101	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A102	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	A103	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
	A104	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
	A105	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	A106	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
	A107	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	A108	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
	A109	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
	A110	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
	A111	6,346,110	2/12/02	Wu	606	108	1/3/01
	A112	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
	A113	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A114	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
	A115	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
	A116	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
	A117	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A118	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
↓	A119	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
BP	A120	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00

BP	A121	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
↑	A122	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A123	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A124	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A125	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A126	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
	A127	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00
	A128	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
	A129	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
	A130	6,572,644	6/3/03	Moein	623	1.11	6/27/01
	A131	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
	A132	6,585,926	7/1/03	Mirzaee	264	400	8/31/00
BP	A133	6,605,154	8/12/03	Villareal	118	500	5/31/01

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
BP	A134	2001/0018469	8/30/01	Chen et al.	523	121	12/28/00
↑	A135	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21/01
	A136	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/19/00
	A137	2002/0091433	7/11/02	Ding et al.	623	1.2	12/17/01
	A138	2002/0155212	10/24/02	Hossainy	427	2.25	4/24/01
BP	A139	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30/02
	A140	2003/0099712	5/29/03	Jayaraman	424	486	11/26/01

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
BP	B1	EP 0 301 856	2/1/89	European			✓	
BP	B2	WO 90/01969	03/08/90	PCT				
BP	B3	WO 91/12846	9/5/91	PCT			✓	
BP	B4	EP 0 514 406	11/25/92	European			✓	
BP	B5	EP 0 604 022	6/29/94	European				
BP	B6	EP 0 623 354	11/9/94	European			✓	
BP	B7	WO 95/10989	4/27/95	PCT				


BP	B8	EP 0 665 023	8/2/95	European				
↑	B9	EP 0 701 802	3/20/96	European				
	B10	EP 0 716 836	6/19/96	European				
	B11	WO 96/40174 ?	12/19/96	PCT				
	B12	WO 97/10011	3/20/97	PCT				
	B13	EP 0 809 999	12/3/97	European				
	B14	WO 97/45105 ?	12/4/97	PCT				
	B15	WO 97/46590	12/11/97	PCT				
	B16	EP 0850651 (A2 & A3)	01/07/98	Europe	A61L	27/00		
	B17	EP 0 832 655	4/1/98	European				
	B18	EP 0875218 (A2 & A3)	04/11/98	Europe	A61F	2/06		
BP	B19	WO 98/17331	4/30/98	PCT			✓	
↑	B20	WO 98/23228	06/04/98	PCT				
	B21	EP 0 850 651	7/1/98	European				
	B22	WO 98/36784	8/27/98	PCT				
	B23	EP 0 879 595	11/25/98	European				
	B24	WO 99/01118 ?	1/14/99	PCT				
↓	B25	JP/11299901	02/11/99	Japan	A61M	29/02		✓
BP	B26	WO 99/16386	04/08/99	PCT	A61F	2/06	✓	
↑	B27	EP 0 910 584	4/28/99	European				
	B28	EP 0 923 953	6/23/99	European				
	B29	WO 99/38546	8/5/99	PCT				
	B30	EP 0 953 320	11/3/99	European				
	B31	WO 99/63981	12/16/99	PCT				
	B32	EP 0 970 711	1/12/00	European				
	B33	WO 00/02599	1/20/00	PCT				
	B34	EP 0 982 041	3/1/00	European				
	B35	WO 00/12147	3/9/00	PCT				
	B36	WO 00/18446	4/6/00	PCT				
↓	B37	WO 00/64506	11/2/00	PCT				
BP	B38	WO 01/01890	1/11/01	PCT				

BP	B39	WO 01/15751	3/8/01	PCT	—		
↑	B40	WO 01/17577	3/15/01	PCT	—		
	B41	WO 01/45763	6/28/01	PCT	—		
	B42	WO 01/49338	7/12/01	PCT	—		
	B43	2001-190687	7/17/01	Japan (Abstract)	—	X	
	B44	WO 01/74414	10/11/01	PCT	—		
	B45	WO 02/03890	1/17/02	PCT	—		
	B46	WO 02/026162	4/4/02	PCT	—		
	B47	WO 02/34311	5/2/02	PCT	—		
	B48	WO 02/056790	7/25/02	PCT	—		
	B49	WO 03/000308	1/3/03	PCT	—		
	B50	EP 1 273 314	1/8/03	European	—		
✓	B51	WO 03/022323	3/20/03	PCT	—		
BP	B52	WO 03/028780	4/10/03	PCT	—		✓
BP	B53	WO 03/037223	5/8/03	PCT	—		✓
BP	B54	WO 03/039612	5/15/03	PCT	—		✓

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

BP	C1	Anonymous, <i>Cardiologists Draw - Up The Dream Stent</i> , Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959 , printed 8/25/03 (2 pages).
BP	C2	Anonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753 , printed 8/25/03 (2 pages).
BP	C3	Anonymous, <i>Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent</i> (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
BP	C4	Anonymous, <i>Stenting continues to dominate cardiology</i> , Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752 , printed 8/25/03 (2 pages).
BP	C5	Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).
BP	C6	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2): 252A (Abstract) (Feb. 1989).
BP	C7	Barbucci et al., <i>Coating of commercially available materials with a new heparinizable material</i> , J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
BP	C8	Chung et al., <i>Inner core segment design for drug delivery control of thermo-responsive polymeric micelles</i> , Journal of Controlled Release 65:93-103 (2000).
BP	C9	Dev et al., <i>Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs</i> , Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
BP	C10	Dichek et al., <i>Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells</i> , Circ. 80(5):1347-1353 (Nov. 1989).
BP	C11	Eigler et al., <i>Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin</i> , JACC, 4A (701-1), Abstract (Feb. 1994).
BP	C12	Helmus, <i>Overview of Biomedical Materials</i> , MRS Bulletin, pp. 33-38 (Sept. 1991).

BP	C13	Herdeg et al., <i>Antiproliferative Stent Coatings: Taxol and Related Compounds</i> , Semin. Intervent. Cardiol. 3:197-199 (1998).
BP	C14	Inoue et al., <i>An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs</i> , Journal of Controlled Release 51:221-229 (1998).
BP	C15	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).
BP	C16	Levy et al., <i>Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants</i> , Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
BP	C17	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
BP	C18	Marconi et al., <i>Covalent bonding of heparin to a vinyl copolymer for biomedical applications</i> , Biomaterials 18(12):885-890 (1997).
BP	C19	Matsumaru et al., <i>Embollic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
BP	C20	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
BP	C21	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
BP	C22	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
BP	C23	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , American Heart Journal 136(6):1081-1087 (Dec. 1998).
BP	C24	Ozaki et al., <i>New Stent Technologies</i> , Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
BP	C25	Pechar et al., <i>Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin</i> , Bioconjugate Chemistry 11(2):131-139 (Mar./Apr. 2000).
BP	C26	Peng et al., <i>Role of polymers in improving the results of stenting in coronary arteries</i> , Biomaterials 17:685-694 (1996).
BP	C27	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
BP	C28	van Beusekom et al., <i>Coronary stent coatings</i> , Coronary Artery Disease 5(7):590-596 (July 1994).
BP	C29	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).
BP	C30	Yokoyama et al., <i>Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor</i> , Journal of Controlled Release 50:79-92 (1998).
EXAMINER		DATE CONSIDERED
Brian Pellegrini		12/23/05
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.		
Include copy of this form with next communication to applicant.		

FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE		Docket No.		Application No.	
US Patent and Trademark Office				50623.245		10/623,908	
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Applicant			
				Paul J. Kawula			
				Filing Date		Group Art Unit	
				July 21, 2003		3731	
U.S. PATENT DOCUMENTS							
Examiner	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
 MAR 21 2003 BP A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A23 A24 A25	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	10/14/33
	A2	2,386,454	10/9/45	Frosch et al.	260	78	11/22/40
	A3	3,773,737	11/20/73	Goodman et al.	260	78	6/9/71
	A4	3,849,514	11/19/74	Gray, Jr. et al.	260	857	9/5/69
	A5	4,226,243	10/7/80	Shalaby et al.	128	335.5	7/27/79
	A6	4,343,931	8/10/82	Barrows	528	291	12/17/79
	A7	4,529,792	7/16/85	Barrows	528	291	5/6/82
	A8	4,611,051	9/9/86	Hayes et al.	528	295.3	12/31/85
	A9	4,656,242	4/7/87	Swan et al.	528	295.3	6/7/85
	A10	4,886,062	12/12/89	Wiktor	128	343	10/19/87
	A11	4,931,287	6/5/90	Bae et al.	424	484	6/14/88
	A12	5,019,096	5/28/91	Fox, Jr. et al.	623	1	10/14/88
	A13	5,100,992	3/31/92	Cohn et al.	424	501	5/3/90
	A14	5,133,742	7/28/92	Pinchuk	623	1	11/14/91
	A15	5,219,980	6/15/93	Swidler	528	272	4/16/92
	A16	5,258,020	11/2/93	Froix	623	1	4/24/92
	A17	5,306,786	4/26/94	Moens et al.	525	437	12/16/91
	A18	5,485,496	1/16/96	Lee et al.	378	64	9/22/94
	A19	5,516,881	5/14/96	Lee et al.	528	320	8/10/94
	A20	5,584,877	12/17/96	Miyake et al.	623	1	6/23/94
	A21	5,607,467	3/4/97	Froix	623	1	6/23/93
	A22	5,610,241	3/11/97	Lee et al.	525	411	5/7/96
	A23	5,616,338	4/1/97	Fox, Jr. et al.	424	423	4/19/91
	A24	5,644,020	7/1/97	Timmermann et al.	528	288	5/10/96
	A25	5,674,242	10/7/97	Phan et al.	606	198	11/15/96

BP	A26	5,711,958	1/27/98	Cohn et al.	424	423	7/11/96
	A27	5,721,131	2/24/98	Rudolph et al.	435	240	4/28/94
	A28	5,723,219	3/3/98	Kolluri et al.	428	411.1	12/19/95
	A29	5,759,205	6/2/98	Valentini	623	16	1/20/95
	A30	5,783,657	7/21/98	Pavlin et al.	528	310	10/18/96
	A31	5,849,859	12/15/98	Acemoglu	528	271	3/23/93
	A32	5,854,376	12/29/98	Higashi	528	288	3/11/96
	A33	5,879,713	3/9/99	Roth et al.	424	489	1/23/97
	A34	5,902,875	5/11/99	Roby et al.	528	310	1/28/98
	A35	5,905,168	5/18/99	Dos Santos et al.	562	590	12/10/93
	A36	5,910,564	6/8/99	Gruning et al.	528	310	12/6/96
	A37	5,914,387	6/22/99	Roby et al.	528	310	1/28/98
	A38	5,919,893	7/6/99	Roby et al.	525	411	1/28/98
	A39	5,932,299	8/3/99	Katoot	427	508	4/22/97
	A40	5,958,385	9/28/99	Tondeur et al.	424	61	9/28/95
	A41	5,962,138	10/5/99	Kolluri et al.	428	411.1	11/24/97
	A42	6,011,125	1/4/00	Lohmeijer et al.	525	440	9/25/98
BP	A43	6,034,204	3/7/00	Mohr et al.	528	328	8/7/98
	A44	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
BP	A45	6,054,553	4/25/00	Groth et al.	528	335	11/12/96
	A46	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
BP	A47	6,120,788	9/19/00	Barrows	424	426	10/16/98
	A48	6,136,333	10/24/00	Cohn et al.	424	423	7/11/97
	A49	6,143,354	11/7/00	Koulik et al.	427	2.24	2/8/99
	A50	6,159,978	12/12/00	Myers et al.	514	252.1	11/24/98
	A51	6,172,167	1/9/01	Stapert et al.	525	420	6/27/97
	A52	6,177,523	1/23/01	Reich et al.	525	459	7/14/99
	A53	6,180,632	1/30/01	Myers et al.	514	252.1	11/24/98
	A54	6,211,249	4/3/01	Cohn et al.	514	772.1	1/13/98
	A55	6,214,901	4/10/01	Chudzik et al.	523	113	4/15/99
	A56	6,245,760	6/12/01	He et al.	514	234.8	11/24/98
BP	A57	6,248,129	6/19/01	Froix	623	1.42	10/23/98

BP	A58	6,258,371	7/10/01	Koulik et al.	424	422	4/3/98
↑	A59	6,262,034	7/17/01	Mathiowitz et al.	514	44	11/25/97
	A60	6,270,788	8/7/01	Koulik et al.	424	423	10/4/99
	A61	6,277,449	8/21/01	Kolluri et al.	427	289	6/30/99
	A62	6,344,035	2/5/02	Chudzik et al.	604	265	10/20/00
	A63	6,387,379	5/14/02	Goldberg et al.	424	400	2/28/94
	A64	6,482,834	11/19/02	Spada et al.	514	311	4/6/01
	A65	6,503,538	1/7/03	Chu et al.	424	497	8/30/00
	A66	6,524,347	2/25/03	Myers et al.	2514	252.1	9/29/00
	A67	6,528,526	3/4/03	Myers et al.	214	311	9/29/00
	A68	6,530,950	3/11/03	Alvarado et al.	623	1.13	8/3/00
	A69	6,530,951	3/11/03	Bates et al.	623	1.45	10/23/97
	A70	6,585,755	7/1/03	Jackson et al.	623	1.15	6/29/01
	A71	6,616,765	9/9/03	Hossaony et al.	623	1.45	1/10/02
	A72	6,623,448	9/23/03	Slater	604	95.01	3/30/01
	A73	6,625,486	9/23/03	Lundkvist et al.	604	21	4/11/01
	A74	6,645,135	11/11/03	Bhat	600	3	3/30/01
	A75	6,645,195	11/11/03	Bhat et al.	604	528	1/5/01
	A76	6,656,216	12/2/03	Hossainy et al.	623	1.13	6/29/01
	A77	6,656,506	12/2/03	Wu et al.	424	489	5/9/01
	A78	6,660,034	12/9/03	Mandrusov et al.	623	1.42	4/30/01
	A79	6,663,662	12/16/03	Pacetti et al.	623	1.13	12/28/00
	A80	6,663,880	12/16/03	Roorda et al.	424	423	11/30/01
	A81	6,666,880	12/23/03	Chiu et al.	623	1.11	6/19/01
	A82	6,673,154	1/6/04	Pacetti et al.	118	500	6/28/01
	A83	6,673,385	1/6/04	Ding et al.	427	2.28	6/28/01
	A84	6,689,099	2/10/04	Mirzaee	604	107	2/27/01
	A85	6,695,920	2/24/04	Pacetti et al.	118	500	6/27/01
↓	A86	6,706,013	3/16/04	Bhat et al.	604	96.01	6/29/01
BP	A87	6,709,514	3/23/04	Hossainy	118	52	12/28/01

BP	A88	6,712,845	3/30/04	Hossainy	623	1.42	4/24/01
↑	A89	6,713,119	3/30/04	Hossainy et al.	427	2.25	12/23/99
	A90	6,716,444	4/6/04	Castro et al.	424	422	9/28/00
	A91	6,723,120	4/20/04	Yan	623	1.15	9/3/02
	A92	6,733,768	5/11/04	Hossainy et al.	424	426	6/25/02
	A93	6,740,040	5/25/04	Mandrusov et al.	600	439	1/30/01
	A94	6,743,462	6/1/04	Pacetti	427	2.24	5/31/01
	A95	6,749,626	6/15/04	Bhat et al.	623	1.1	11/17/00
	A96	6,753,071	6/22/04	Pacetti et al.	428	212	9/27/01
	A97	6,758,859	7/6/04	Dang et al.	623	1.15	10/30/00
↓	A98	6,759,054	7/6/04	Chen et al.	424	423	12/28/00
BP	A99	6,764,505	7/20/04	Hossainy et al.	623	1.15	4/12/01

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date If Appropriate
BP	A100	2001/0007083	7/5/01	Roorda	623	1.15	12/21/00
↑	A101	2001/0014717	8/16/01	Hossainy et al.	525	60	12/28/00
	A102	2001/0020011	9/6/01	Mathiowitz et al.	514	44	3/23/01
	A103	2001/0029351	10/11/01	Falotico et al.	604	103.02	5/7/01
	A104	2001/0051608	12/13/01	Mathiowitz et al.	514	44	10/15/98
	A105	2002/0005206	1/17/02	Falotico et al.	128	898	5/7/01
	A106	2002/0007213	1/17/02	Falotico et al.	623	1.21	5/7/01
	A107	2002/0007214	1/17/02	Falotico	623	1.21	5/7/01
	A108	2002/0007215	1/17/02	Falotico et al.	623	1.21	5/7/01
	A109	2002/0009604	1/24/02	Zamora et al.	428	450	12/21/00
	A110	2002/0016625	2/7/02	Falotico et al.	623	1.13	5/7/01
	A111	2002/0032414	3/14/02	Ragheb et al.	604	265	5/7/01
	A112	2002/0032434	3/14/02	Chudzik et al.	604	890.1	11/21/01
	A113	2002/0051730	5/2/02	Bodnar et al.	422	33	9/28/01
	A114	2002/0071822	6/13/02	Uhrich	424	78.37	7/27/01
↓	A115	2002/0082679	6/27/02	Sirhan et al.	623	1.15	11/1/01
BP	A116	2002/0087123	7/4/02	Hossainy et al.	604	198	1/2/01

BP	A117	2002/0094440	7/18/02	Llanos et al.	428	421	9/25/01
	A118	2002/0111590	8/15/02	Davila et al.	604	265	9/25/01
	A119	2002/0120326	8/29/02	Michal	623	1.15	12/22/00
	A120	2002/0123801	9/5/02	Pacetti et al.	623	1.46	12/28/00
	A121	2002/0142039	10/3/02	Claude	424	486	3/30/01
	A122	2002/0165608	11/7/02	Llanos et al.	623	1.45	6/22/01
	A123	2002/0176849	11/28/02	Slepian	424	93.7	2/8/02
	A124	2002/0183581	12/5/02	Yoe et al.	600	3	5/31/01
	A125	2002/0188037	12/12/02	Chudzik et al.	523	112	6/18/02
	A126	2002/0188277	12/12/02	Roorda et al.	604	523	5/18/01
	A127	2003/0004141	1/2/03	Brown	514	152	3/8/02
	A128	2003/0028243	2/6/03	Bates et al.	623	1.15	8/14/02
	A129	2003/0028244	2/6/03	Bates et al.	623	1.15	8/14/02
	A130	2003/0031780	2/13/03	Chudzik et al.	427	2.1	10/10/02
	A131	2003/0032767	2/13/03	Tada et al.	528	310	2/5/01
	A132	2003/0036794	2/20/03	Ragheb et al.	623	1.15	8/19/02
	A133	2003/0039689	2/27/03	Chen et al.	424	468	4/26/02
	A134	2003/0040712	2/27/03	Ray et al.	604	173	10/10/02
	A135	2003/0040790	2/27/03	Furst	623	1.11	7/31/02
	A136	2003/0059520	3/27/03	Chen et al.	427	2.1	9/27/01
	A137	2003/0060877	3/27/03	Falotico et al.	623	1.42	4/15/02
	A138	2003/0072868	4/17/03	Harish et al.	427	2.24	11/25/02
	A139	2003/0073961	4/17/03	Happ	604	274	9/28/01
	A140	2003/0083646	5/1/03	Sirhan et al.	604	891.1	12/14/01
	A141	2003/0083739	5/1/03	Cafferata	623	1.42	9/24/02
	A142	2003/0097088	5/22/03	Pacetti	604	19	11/12/01
	A143	2003/0097173	5/22/03	Dutta	623	1.38	1/10/03
	A144	2003/0105518	6/5/03	Dutta	623	1.38	1/10/03
	A145	2003/0113439	6/19/03	Pacetti et al.	427	2.24	11/18/02
	A146	2003/0150380	8/14/03	Yoe	118	423	2/19/03
	A147	2003/0157241	8/21/03	Hossainy et al.	427	2.24	3/5/03
✓	A148	2003/0158517	8/21/03	Kokish	604	103.01	2/11/03
BP	A149	2003/0190406	10/9/03	Hossainy et al.	427	2.25	4/10/03

BP	A150	2003/0207020	11/6/03	Villareal	427	2.24	4/22/03
↑	A151	2003/0211230	11/13/03	Pacetti et al.	427	2.24	4/7/03
	A152	2004/0018296	1/29/04	Castro et al.	427	2.25	6/23/03
	A153	2004/0029952	2/12/04	Chen et al.	514	449	8/1/03
	A154	2004/0047978	3/11/04	Hossainy et al.	427	2.1	8/12/03
	A155	2004/0047980	3/11/04	Pacetti et al.	427	2.25	9/8/03
	A156	2004/0052858	3/18/04	Wu et al.	424	490	9/15/03
	A157	2004/0052859	3/18/04	Wu et al.	424	490	9/15/03
	A158	2004/0054104	3/18/04	Pacetti	526	242	9/5/02
	A159	2004/0060508	4/1/04	Pacetti et al.	118	264	9/12/03
	A160	2004/0062853	4/1/04	Pacetti et al.	427	2.1	10/2/03
	A161	2004/0063805	4/1/04	Pacetti et al.	523	113	9/19/02
	A162	2004/0071861	4/15/04	Mandrusov et al.	427	2.24	10/2/03
	A163	2004/0072922	4/15/04	Hossainy et al.	523	113	10/9/02
	A164	2004/0073298	4/15/04	Hossainy	623	1.46	10/8/03
	A165	2004/0086542	5/6/04	Hossainy et al.	424	423	12/16/02
	A166	2004/0086550	5/6/04	Roorda et al.	424	448	10/24/03
↓	A167	2004/0096504	5/20/04	Michal	424	471	11/12/03
BP	A168	2004/0098117	5/20/04	Hossainy et al.	623	1.42	9/22/03

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
BP	B1	SU 872531	10/15/81	SU (English Abstract)	—	—		
BP	B2	SU 876663	10/30/81	SU (English Abstract)	—	—		
BP	B3	SU 905228	2/15/82	SU (English Abstract)	—	—		
BP	B4	SU 790725	2/9/83	SU (English Abstract)	—	—		
BP	B5	SU 1016314	5/7/83	SU (English Abstract)	—	—		
BP	B6	SU 811750	9/23/83	SU (English Abstract)	—	—		
✓	B7	SU 1293516	2/28/87	SU (English Abstract)	—	—		
BP	B8	EP 0 396 429	11/7/90	European	—	—		
BP	B9	DE 42 24 401	1/27/94	Germany	—	—	X	
BP	B10	WO 94/09760	5/11/94	PCT	—	—	✓	
BP	B11	WO 95/24929	9/21/95	PCT	—	—	✓	
BP	B12	WO 98/08463	3/5/98	PCT	—	—	✓	

BP	B13	WO 98/17331	4/30/98	PCT				
BP	B14	WO 98/32398	7/30/98	PCT				
BP	B15	EP 1 023 879	8/2/00	EPO				
BP	B16	WO 01/51027	7/19/01	PCT				
BP	B17	EP 1 192 957	4/3/02	EPO				
BP	B18	WO 02/058753	8/1/02	PCT				
BP	B19	WO 02/102283	12/27/02	PCT				
BP	B20	WO 03/080147	10/2/03	PCT				
BP	B21	WO 03/082368	10/9/03	PCT				
BP	B22	WO 04/000383	12/31/03	PCT				
BP	B23	WO 04/009145	1/29/04	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
BP	C1	Katsarava et al., <i>Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α-amino acid)α,ω-Alkylene Diesters, and Aliphatic Dicarboxylic Acids</i> , Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).						
BP	C2	Saitome, et al., <i>Novel Enzymatically Degradable Polymers Comprising α-Amino Acid, 1,2-Ethanediol, and Adipic Acid</i> , Chemistry Letters, pp. 21-24, (1991).						
EXAMINER			DATE CONSIDERED					
Brian Bellay			12/23/05					
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								